Accurate and comprehensive neoantigen detection and characterization requires the use of an exome-scale assay since neoantigens can arise from somatic alterations occurring in any gene of the genome (Garofalo et al., 2016). In addition, because only expressed neoantigens are potential candidates for personalized cancer therapy development, it is imperative to analyze not only the DNA of a tumor sample, but also the RNA.
ImmunoID NeXT is a broad immunogenomics platform that combines Personalis’ augmented and analytically-validated NeXT Exome and NeXT Transcriptome, with uniquely enhanced features that are key for the development of personalized cancer therapies.
The following features are incorporated into the ImmunoID NeXT for optimal neoantigen identification:
Personalis’ proprietary Accuracy and Content Enhanced (ACE) Technology augments coverage of complex and difficult-to-sequence regions (e.g. areas of high-GC content) across all ~20,000 genes that are typically poorly covered or completely missed with conventional approaches.
The ~300X and ~150X mean coverage for the tumor and normal, respectively, enables the highly-sensitive and specific detection of single nucleotide variants (SNVs), insertions/deletions (indels), and gene fusions, any of which may produce potentially-immunogenic neoantigens.
HLA typing is an essential component of the neoantigen prediction process. Leveraging the DNA data derived from the NeXT assay, ImmunoID NeXT utilizes in silico typing of both HLA Class I and Class II loci. Our HLA typing validation study demonstrates that ImmunoID NeXT produces robust and accurate HLA typing.
Integration of both proprietary and publicly-available advanced analytical algorithms and tools to generate high quality and informative analytical reports.
The dual extraction of DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor samples maximizes the data generated from each.